Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial

NCT06700798 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma(MZL)

Interventions

DRUG: Orelabrutinib
DRUG: rituximab
DRUG: Cyclophosphamide
DRUG: Vincristine
DRUG: Prednisone tablet

Sponsor

Fei Li